Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8639644 | 0.79 | ALDH1A1 (0.46) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| Calcium SCHEMBL31193385 | 0.77 | ALDH1A1 (0.45) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| Bicarbonate SCHEMBL8638060 | 0.76 | ALDH1A1 (0.44) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14269820 | 0.74 | ALDH1A1 (0.45) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL20913010 | 0.72 | ALDH1A1 (0.38) | ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL10192810 | 0.70 | HSD17B10 (0.52) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL15255433 | 0.69 | ALDH1A1 (0.43) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL170644 | 0.69 | CA1 (0.39) | ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL5697291 | 0.68 | ALDH1A1 (0.49) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL28122971 | 0.68 | ALDH1A1 (0.38) | ALDH1A1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080032975-A1 | Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2008-02-07 | — | — | US | disclosed |
| US-7282498-B2 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION (US) | 2007-10-16 | — | — | US | disclosed |
| US-20050059826-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION | 2005-03-17 | — | — | US | disclosed |
| US-6852730-B2 | Substituted fused pyrazolecarboxylic acid arylamides and related compounds | NEUROGEN CORPORATION (US) | 2005-02-08 | — | — | US | disclosed |
| US-6743817-B2 | AGONISTS, ANTAGONISTS OR INVERSE AGONISTS FOR BRAIN RECEPTORS; ANXIOLYTICS, ANTIDEPRESSANTS, TREATING SLEEP AND PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2004-06-01 | — | — | US | disclosed |
| US-6656941-B2 | Aryl substituted tetrahydroindazoles | NEUROGEN CORPORATION | 2003-12-02 | — | — | US | disclosed |
| US-20030216379-A1 | Substituted fused pyrazolecarboxylic acid arylamides and related compounds | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2003-11-20 | — | — | US | disclosed |
| US-20020128236-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION | 2002-09-12 | — | — | US | disclosed |
| US-6395905-B1 | GABA-A ALPHA 5 LIGANDS USEFUL FOR ENHANCING COGNITION: | MERCK SHARP & DOHME LTD. (GB) | 2002-05-28 | — | — | US | disclosed |
| US-20020055524-A1 | Novel aryl substituted tetrahydroindazoles as ligands of the GABA receptor | NEUROGEN CORPORATION | 2002-05-09 | — | — | US | disclosed |
| EP-1140855-A1 | TETRAHYDROINDAZOLE DERIVATIVES AS LIGANDS FOR GABA-A ALPHA 5 RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040565-A1 | TETRAHYDROINDAZOLE DERIVATIVES AS LIGANDS FOR GABA-A ALPHA 5 RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216379-A1 | Substituted fused pyrazolecarboxylic acid arylamides and related compounds | GABRA5, GABRA2, GABRA1 | ALDH1A1 429/4885MAPT 397/4885CYP1A2 61/4885 |
| US-20050059826-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NPSR1, GABRE, CHRNE | ALDH1A1 1595/4885MAPT 1612/4885CYP1A2 205/4885 |
| US-20020128236-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | HTR1A, GABRA1, GABRE | ALDH1A1 1030/4885MAPT 1610/4885CYP1A2 211/4885 |
| US-20020055524-A1 | Novel aryl substituted tetrahydroindazoles as ligands of the GABA receptor | GABRA1, GABRB1, GABRA3 | ALDH1A1 622/4885MAPT 1001/4885CYP1A2 201/4885 |
| US-20080032975-A1 | Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes | NPSR1, GABRE, CHRNE | ALDH1A1 1595/4885MAPT 1612/4885CYP1A2 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.